Publications by authors named "Jennifer McCasland"
Oncoimmunology
April 2022
Article Synopsis
- Immune checkpoint inhibitors (ICI) have improved cancer treatment, but many patients don’t benefit due to potential tumor and genetic factors.
- Researchers used Diversity Outbred (DO) and Collaborative Cross (CC) mouse models to study how host genetics affect ICI responses, identifying significant genetic regions linked to therapeutic outcomes.
- Notably, they discovered that prolactin, an immunomodulating cytokine, enhances ICI effectiveness, as indicated by increased tumor response and immune cell infiltration in mice treated with prolactin.
